Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

American customers' interest in their genetic ancestry continues to be the primary driver of the consumer genomics market and shows no signs of diminishing. 

At the JP Morgan Healthcare conference, Illumina unveiled the semiconductor-based sequencing system it has been developing as part of its Firefly project.

Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.

The investment bank said it changed its rating because of where the company is in its latest new product adoption cycle with the NovaSeq.

More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair. 

Genome Medical will use the proceeds of its Series A-1 financing to expand its nationwide footprint, as well as to invest in its telegenomics platform.

The investment bank said that Danaher, Illumina, Qiagen, and Thermo Fisher Scientific were its top picks. 

The firms plan to customize Illumina's MiniSeq for China Food and Drug Administration approval for oncology testing. 

The investment bank said that it thinks 2018 will be a good year for clinical sequencing and that overall demand for high-throughput sequencing remains high. 

With a two-stage atrial fibrillation GWAS, researchers took a crack at untangling the pathways, regulatory features, and tissue types contributing to the heart condition.

Pages

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.